Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

22/01/2015 - 2 minutes

NovaBiotics Ltd has raised €6,5M for priority clinical stage first-in-class antimicrobial therapeutics assets. The private placement with Woodford Investment Management LLP was arranged by Shore Capital as financial adviser and broker to the company.

NovaBiotics is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. NovaBiotics has spent more than 10 years developing a treatment for nail fungus. The US market alone is expected to be worth about €2,6 billion a year by 2020, which underlines the potential for NovaBiotics and its Novexatin product.

NovaBiotics is also focused on further developing its earlier stage antifungal and antibacterial compounds and the anti-infective peptide platform from which these molecules have been derived.

NovaBiotics’ therapeutic candidates possess a novel mode of antimicrobial action. Their antifungal and antibacterial compounds have demonstrated superiority over many existing anti-infective drug classes thus far. Furthermore, their mechanism of action is such that the opportunity for antimicrobial resistance developing in the bacteria and fungi which NovaBiotics’ novel compounds target is minimised if not negated.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!